Literature DB >> 3092732

Discrepancies between disk diffusion and broth susceptibility studies of the activity of ticarcillin plus clavulanic acid against ticarcillin-resistant Pseudomonas aeruginosa.

F A Manian, R H Alford.   

Abstract

Ticarcillin and clavulanic acid in combination were tested against 40 Pseudomonas aeruginosa isolates resistant to ticarcillin by disk diffusion. A total of 21 isolates (53%) were susceptible to ticarcillin-clavulanate by disk diffusion, under currently recommended criteria for ticarcillin susceptibility. Macro-broth dilution tests (ticarcillin plus clavulanic acid, 2 micrograms/ml) confirmed susceptibility (MIC less than or equal to 64 micrograms/ml) of only 8 (38%) of 21 isolates. Time-kill studies of disk diffusion susceptible isolates indicated 2 log10 or greater killing of most isolates at 6 h in broth containing ticarcillin (64 micrograms/ml) combined with clavulanic acid (1, 2, 5, or 10 micrograms/ml). After 6 h, regrowth was common in all concentrations of clavulanic acid except 10 micrograms/ml. Regrowth populations were resistant to ticarcillin-clavulanate by MIC determination. Poor bactericidal activity of ticarcillin-clavulanate against ticarcillin-resistant P. aeruginosa was confirmed, as most isolates did not undergo 99.9% or greater killing at 24 h in all concentrations of clavulanic acid. Serotype O-11 was our most common serotype and was associated with disk diffusion "pseudosusceptibility." Concomitant disk diffusion testing of ticarcillin-clavulanate and ticarcillin is recommended for testing the susceptibility of P. aeruginosa to ticarcillin-clavulanate by disk diffusion. P. aeruginosa isolates resistant to ticarcillin should as a rule be considered also resistant to ticarcillin-clavulanate, despite apparent susceptibility by disk diffusion.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3092732      PMCID: PMC176430          DOI: 10.1128/AAC.30.1.35

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

2.  Combined activitiy of clavulanic acid and ticarcillin against ticarcillin-resistant, gram-negative bacilli.

Authors:  J W Paisley; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

3.  In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin.

Authors:  P A Hunter; K Coleman; J Fisher; D Taylor
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

4.  Regrowth of Pseudomonas aeruginosa and other bacteria after the bactericidal action of carbenicillin and other beta-lactam antibiotics.

Authors:  M N Gwynn; T L Webb; G N Rolinson
Journal:  J Infect Dis       Date:  1981-09       Impact factor: 5.226

5.  In vitro activity of ticarcillin plus clavulanic acid (BRL 28500, 'Timentin') against ticarcillin-resistant gram-negative rods.

Authors:  B Chattopadhyay; I Hall
Journal:  Curr Med Res Opin       Date:  1984       Impact factor: 2.580

6.  Clavulanic acid, a novel inhibitor of beta-lactamases.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

7.  Ticarcillin for treatment of serious infections with gram-negative bacteria.

Authors:  M G Parry; H C Neu
Journal:  J Infect Dis       Date:  1976-11       Impact factor: 5.226

8.  In vitro activities of enoxacin, ticarcillin plus clavulanic acid, aztreonam, piperacillin, and imipenem and comparison with commonly used antimicrobial agents.

Authors:  D Henry; A G Skidmore; J Ngui-Yen; A Smith; J A Smith
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

9.  Comparison between agar and broth minimum inhibitory concentrations of cefamandole, Cefoxitin, and cefuroxime.

Authors:  M Rylander; J E Brorson; J Johnsson; R Norrby
Journal:  Antimicrob Agents Chemother       Date:  1979-04       Impact factor: 5.191

10.  Cefoperazone in the treatment of severe or complicated infections.

Authors:  R R Bailey; B Peddie; E Blake; V Bishop; J Reddy
Journal:  Drugs       Date:  1981       Impact factor: 9.546

View more
  1 in total

1.  Stenotrophomonas maltophilia: emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model.

Authors:  M W Garrison; D E Anderson; D M Campbell; K C Carroll; C L Malone; J D Anderson; R J Hollis; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.